FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2134-2135 May 19, 2005 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Cazzola, M. Related Article by List, A. PubMed Citation

To the Editor: List et al. (Feb. 10 issue)¹ report encouraging results with regard to the efficacy of lenalidomide, a thalidomide analogue, in the treatment of patients with myelodysplastic syndromes and symptomatic anemia whose condition failed to respond to erythropoietin. List et al. tested three dosing regimens, but little is said about their advantages or disadvantages. It appears that the lowest dosing regimen (10 mg per day for 21 days in a 28-day cycle) produced the best response with the least toxicity, but it is unclear what the median duration of response and the number of cytogenetic responses were with . . . [Full Text of this Article]

This article has been cited by other articles:

• Kase, C. S. (2005). Hemostatic Treatment in the Early Stage of Intracerebral Hemorrhage: The Recombinant Factor VIIa Experience. Stroke 36: 2321-2322 [Full Text]